Summary
The product Aromasin, submitted by the manufucturer acepharmaadmin@protonmail.com, underwent independent testing to verify its authenticity and potency. The sample was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Exemestane, with a concentration of 24.90 mg.
The testing process began on 2 May 2024, with the sample received on 7 May 2024, and analysis completed on 10 May 2024. The manufacturer and batch number were not provided, and the sample description lacked detailed information. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unknown
- Product Name: Aromasin
- Active Ingredient: Exemestane
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing [H4]
- Task Number: #41898
- Testing Ordered: 2 May 2024
- Sample Received: 7 May 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: ACE Pharmaceuticals (Manufacturer)
- Analysis Paid For By: ACE Pharmaceuticals (Manufacturer)
Testing Results [H4]
- Specification: Qualitative and quantitative analysis of an AAS sample
- Measured Concentration: 24.90 mg
- Accuracy: 99.60% (0.40% above the label claim)
- Variance: -0.40%
Verification Details [H3]
- Verification URL: https://janoshik.com/tests/41898_GSHVLQCK2AJI
Evaluation of Client-Submitted Testing
This analysis highlights the presence of Exemestane in the tested sample. However, the lack of detailed sample information and batch number warrants careful evaluation. Client-submitted testing may involve inherent biases; independent validation through third-party testing across multiple batches is recommended to ensure product consistency and reliability.
Conclusion
The analysis confirms the presence of Exemestane in the sample, with a measured concentration of 24.90 mg. This result reflects the need for additional testing and detailed sample information to ensure product consistency and reliability. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
